<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03388593</url>
  </required_header>
  <id_info>
    <org_study_id>ZS-01-306</org_study_id>
    <nct_id>NCT03388593</nct_id>
  </id_info>
  <brief_title>Study of the Survival of Recombinant Human Neuregulin-1β in Chronic Heart Failure (CHF) Patients</brief_title>
  <official_title>A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zensun Sci. &amp; Tech. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zensun Sci. &amp; Tech. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy of rhNRG-1 in reducing the death rate of
      heart failure subjects with baseline NT-proBNP level &lt;1600 pg/mL and NYHA class II to III.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The mortality of chronic heart failure patients remains high, in spite of current treatment.
      RhNRG-1(recombinant human neuregulin-1)directly work on the cardiomyocyte and restored the
      normal structure and function of it. Both the preclinical trials, phase II clinical trials
      and already completed phase III clinical trails have confirmed that rhNRG-1 effectively
      enhance the heart function, reverse the remodeling of left ventricular, and reduce all-cause
      mortality in heart failure animals and humans. More importantly, rhNRG-1 can significantly
      reduce the mortality of heart failure subjects with baseline NT-proBNP level &lt;1600 fmol/mL
      and NYHA class II to III. In this phase III study, the investigators will further confirm the
      efficacy of rhNRG-1 in reducing the death rate of heart failure subjects with baseline
      NT-proBNP level &lt;1600 pg/mL and NYHA class II to III.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality caused by cardiovascular events</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality of female subjects</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality of male subjects</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of all-cause re-hospitalization</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with re-hospitalization caused by worsening heart failure</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of NT-proBNP level at the 25th week and 52th week</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) functional classification</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in addition to standard therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhNRG-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rhNRG-1 in addition to standard therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhNRG-1</intervention_name>
    <description>10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks</description>
    <arm_group_label>rhNRG-1</arm_group_label>
    <other_name>NEUCARDIN ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>10 hours per day i.v drip for the first 10 days (0ug/kg/day), followed by weekly 10 minutes i.v bolus (0ug/kg/day), from the 3rd week for 23 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Age between 18 and 75, gender balance (no more than 850 subjects of either gender
             in total 1600 subjects).

          -  2. Left ventricular ejection fraction (LVEF)≤40% (ECHO).

          -  3. Subjects with chronic heart failure (NYHA class II OR III ).

          -  4. NT-proBNP &lt;1600 pg/ml.

          -  5.Diagnosed as chronic systolic heart failure (history, symptoms, signs), and in
             stable condition in the last one month.

          -  6. Receiving standard therapy for chronic heart failure, reach target dose or max
             tolerable dose for one month, or has not changed the dose for one month before
             randomization.

          -  7. Capable of signing the informed consent form.

        Exclusion Criteria:

          -  1.new chronic heart failure patients, or patients receiving standard therapy on
             chronic heart failure for less than 3 months.

          -  2. NYNA functional class I OR IV.

          -  3. NT-proBNP &gt;=1600 pg/ml (by roche assay Kit of guangzhou jinzhe medical center).

          -  4. Patients with acute MI, hypertrophic cardiomyopathy, constrictive pericarditis,
             significant valvular pathological change or congenital heart diseases, primary or
             secondary severe pulmonary artery hypertension.

          -  5. Ischemic heart failure without recanalization or with recanalization in recent six
             months.

          -  6. acute MI in the last 3 months.

          -  7. unstable angina.

          -  8. Patients with acute pulmonary edema or acute hemodynamic disorder.

          -  9. Chronic heart failure patients with acute hemodynamic disorder or acute
             decompensation in the last 1 month (symptoms and signs suggest worsening chronic heart
             failure and may require intravenous drug therapy).

          -  10. Patients with right heart failure caused by pulmonary disease.

          -  11. Patients diagnosed with pericardial effusion or pleural effusion, or evidenced by
             B-type ultrasonic (&gt;50ml).

          -  12. Cardiac surgery or cerebrovascular accident within recent six months.

          -  13. Preparing for heart transplantation or CRT, or has received CRT.

          -  14. Serious ventricular arrhythmia (sustained ventricular tachycardia or frequent
             paroxysmal ventricular tachycardia).

          -  15.Diagnosis of perinatal or chemotherapy-induced cardiomyopathy in last 12 months.

          -  16. Serious hepatic or renal dysfunction (bilirubin 1.5 times above the normal upper
             limit, AST or ALT 2 times above the normal upper limit, serum creatinine＞2.0mg/dL, HBV
             or HCV positive).

          -  17. Serum potassium &lt;3.2 mmol/L or &gt;5.5 mmol/L.

          -  18. Systolic blood pressure &lt;90mmHg or &gt;160mmHg.

          -  19. Women of childbearing age who have a pregnancy plan within 2 years (women of
             childbearing age are defined as women who have a pregnancy physiology).

          -  20. Pregnant or lactating women.

          -  21. Patients who participated in any clinical trial in the recent three months.

          -  22. Subject with a life expectancy less than 6 months as assessed by the investigator.

          -  23. Serious nervous system diseases (Alzheimer's disease, advanced Parkinsonism),lower
             limb defects, or deaf-mute.

          -  24. History of any malignancy or suffering from cancer, or biopsy proven pre-malignant
             condition (e.g., DICS or cervical atypia).

          -  25. Evidence (physical examination, chest X-ray (CXR), ECHO or other tests) shows some
             active malignancy or adenoidal hypertrophy or neoplasm that has an effect on heart
             function or the endocrine system, e.g., pheochromocytoma or hyperthyroidism (Thyroid
             nodules with normal thyroid function do not need to be excluded).

          -  26. As judged by the investigator that the subject cannot complete the study or adhere
             to the study requirements (due to the management reasons or others).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Runlin Gao, Ph.D,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai Hospital and Cardiovascular Institute, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaorui Wang, Ph.D</last_name>
    <phone>86-21-50802627</phone>
    <phone_ext>196</phone_ext>
    <email>wangxiaorui@zensun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Runlin Gao, Ph.D,MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Jingmei Group General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianping Luo</last_name>
    </contact>
    <investigator>
      <last_name>Jianping Luo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fuwai Hospital and Cardiovascular Institute, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jian Zhang, MD, Ph.D</last_name>
      <phone>86-10-88398772</phone>
    </contact>
    <investigator>
      <last_name>Jian Zhang, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital of Chinese People's Liberation Army</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Dong, MD, Ph.D</last_name>
      <phone>86-13621361652</phone>
    </contact>
    <investigator>
      <last_name>Wei Dong, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University Shougang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hongyu Wang</last_name>
    </contact>
    <investigator>
      <last_name>Hongyu Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chongqing Three Gorges Central Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaohua Pang</last_name>
    </contact>
    <investigator>
      <last_name>Xiaohua Pang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xinqiao Hospital, the Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yaoming Song</last_name>
    </contact>
    <investigator>
      <last_name>Yaoming Song</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haikou People's Hospital</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hairong Chen</last_name>
    </contact>
    <investigator>
      <last_name>Hairong Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fourth Hospital Affiliated to Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lixiu Sun</last_name>
    </contact>
    <investigator>
      <last_name>Lixiu Sun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Luoyang</name>
      <address>
        <city>Luoyang</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qunsheng Zhang</last_name>
    </contact>
    <investigator>
      <last_name>Qunsheng Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Provincial Chest Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan Chen</last_name>
    </contact>
    <investigator>
      <last_name>Juan Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital Affiliated to Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ling Li</last_name>
    </contact>
    <investigator>
      <last_name>Ling Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital Affiliated to Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lin Wang</last_name>
    </contact>
    <investigator>
      <last_name>Lin Wang, MD,Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central South University Xiangya School of Medicine</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qun Qin</last_name>
    </contact>
    <investigator>
      <last_name>Qun Qin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shangsha Central Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luping Jiang</last_name>
    </contact>
    <investigator>
      <last_name>Luping Jiang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shuiping Zhao</last_name>
    </contact>
    <investigator>
      <last_name>Shuiping Zhao, MD,Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhijun Huang</last_name>
    </contact>
    <investigator>
      <last_name>Zhijun Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Baotou Medical College of Inner Mongolia University of Science &amp; Technology</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xuefeng Lin</last_name>
    </contact>
    <investigator>
      <last_name>Xuefeng Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical College</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yong Xia</last_name>
    </contact>
    <investigator>
      <last_name>Yong Xia, MD,Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jiangsu University</name>
      <address>
        <city>Zhenjiang</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jinchuan Yan</last_name>
    </contact>
    <investigator>
      <last_name>Jinchuan Yan, MD,Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jilin Provincial People's Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xuelian Zhang</last_name>
    </contact>
    <investigator>
      <last_name>Xuelian Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jilin University Sino-Japanese Friendship Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fanbo Meng</last_name>
    </contact>
    <investigator>
      <last_name>Fanbo Meng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siping Central People's Hospital</name>
      <address>
        <city>Siping</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianzhong Wang</last_name>
    </contact>
    <investigator>
      <last_name>Jianzhong Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital Affiliated to China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shumei Ma</last_name>
    </contact>
    <investigator>
      <last_name>Shumei Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Li Li, MD,Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Li Li, MD,Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renji Hospital, Medical School of Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ben He, MD,Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Ben He, MD,Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, Medical School of Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guoping Lu, MD,Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Guoping Lu, MD,Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ru Ding</last_name>
    </contact>
    <investigator>
      <last_name>Ru Ding</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Fengxian District Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shanghai Oriental hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huimin Fan</last_name>
    </contact>
    <investigator>
      <last_name>Huimin Fan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Yangpu District Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Central Hospital of Putuo District, Shanghai</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zongying Liu, MD,Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Zongying Liu, MD,Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital Affiliated to Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiahong Xu</last_name>
    </contact>
    <investigator>
      <last_name>Jiahong Xu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taiyuan City Central Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaoping Chen</last_name>
    </contact>
    <investigator>
      <last_name>Xiaoping Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huaxi Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hongde Hu</last_name>
    </contact>
    <investigator>
      <last_name>Hongde Hu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sichuan Provincial Peoples Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hong Kong</last_name>
    </contact>
    <investigator>
      <last_name>Hong Kong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Southwest Medical University</name>
      <address>
        <city>Luzhou</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jian Feng</last_name>
    </contact>
    <investigator>
      <last_name>Jian Feng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second People's Hospital of Neijiang</name>
      <address>
        <city>Neijiang</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ze Wang</last_name>
    </contact>
    <investigator>
      <last_name>Ze Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kunming General Hospital of Chengdu Military Region</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lixia Yang</last_name>
    </contact>
    <investigator>
      <last_name>Lixia Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Kunming Medical College</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ge Zhang</last_name>
    </contact>
    <investigator>
      <last_name>Ge Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taizhou Hospital of Zhejiang Province</name>
      <address>
        <city>Linhai</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianjun Jiang</last_name>
    </contact>
    <investigator>
      <last_name>Jianjun Jiang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Quzhou people's hospital</name>
      <address>
        <city>Quzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaoming Tu</last_name>
    </contact>
    <investigator>
      <last_name>Xiaoming Tu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Sixth People's Hospital, Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <zip>shanghai</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2017</study_first_submitted>
  <study_first_submitted_qc>December 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2018</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic heart failure</keyword>
  <keyword>neuregulin</keyword>
  <keyword>mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

